Avalon BioVentures β Full Portfolio
29 tracked investments Β· listed companies and verified rows first
Clinical-stage company developing tumor-activated immunotherapies using masking platform technology.
Valora Therapeutics is a biotech company developing antibody-lectin chimera (AbLec) therapeutics that target cell-surface glycans for immuno-oncology and immunotherapy applications.
BiotechHealthtech
Miguel Garcia-Guzman(Co-Founder, CEO & Director)James Lee(VP, Business Development)Carolyn Bertozzi(Scientific Co-Founder)Jessica Stark(Scientific Co-Founder)
AristaMD is a technology-enabled clinical services provider that connects primary care physicians with board-certified specialists through eConsults to improve access to specialty care and reduce costs.
Digital HealthEnterprise SoftwareHealthtechSaaSSan Diego, US
Keith Pinter(Chief Executive Officer)Julia Jezmir(President and Chief Medical Officer)Brooke LeVasseur(Executive Officer, Director)Craig Cimini(Director)
BoardJohn Kuelper(Director)Tighe Reardon(Executive Officer, Director)
Board seatJay B. LichterΒ· per SEC Form D Β· $1.4M raise Β· filed Mar 2016
BiotechLa Jolla, US
Jay Lichter(Director)Court Turner(Executive Officer, Director)
BoardTighe Reardon(Executive Officer, Director)
Board seatJay B. LichterΒ· per SEC Form D Β· $5.1M raise Β· filed Nov 2016
BiotechLa Jolla, US
Morana Jovan-Embiricos(Director)Anthony Rosenberg(Director)Neil W. Gibson, Ph.D.(Executive Officer, Director)Owen Hughes(Director)
Board seatJay B. LichterΒ· per SEC Form D Β· $10M raise Β· filed Mar 2022
Enlaza Therapeutics develops covalent protein therapeutics using its War-Lock technology, which incorporates proprietary unnatural amino acids into protein drugs so they form irreversible covalent bonds with disease-related targets.
BiotechDeep TechSan Diego, US
Sergio Duron(Co-Founder & Chief Executive Officer)Sanford Madigan(Co-Founder, President & Chief Business Officer)Analeah Heidt(Chief Scientific Officer)
Board seatJay B. LichterΒ· per SEC Form D
Clinical-stage biotech using its RAPID chemoproteomics platform to drug challenging targets; acquired by Otsuka in 2024.
Boston, US
Board seatKevin J. KinsellaΒ· per SEC Form D
Clinical-stage biotech expanding the genetic alphabet with synthetic nucleotides; acquired by Sanofi for $2.5B in 2020.
La Jolla, US
Board seatJay B. LichterΒ· per SEC Form D
BioSpace is a platform providing news, job listings, and recruitment marketing solutions for the life sciences industry.
BiotechHealthtechHR TechMarketing TechMedia & EntertainmentMedical DevicesSaaSDes Moines, US
Josh Goodwin(CEO)
HealthtechLa Jolla, US
Ahmet Tutuncu, M.D., Ph.D.(Executive Officer, Director)
BoardTighe Reardon(Executive Officer)Heather Preston, M.D.(Director)Jay B. Lichter, Ph.D.(Director)Sanford Madigan, Ph.D.(Director)John Stuart Patton, Ph.D.(Director)
Pet therapeutics company developing innovative treatments for dogs and cats; acquired by Elanco Animal Health in 2019.
Arialys Therapeutics develops precision medicines targeting pathogenic autoantibodies in the brain to treat neuropsychiatric disorders driven by autoimmune disease.
BiotechDigital HealthMedical DevicesLa Jolla, US
Peter Flynn, Ph.D.(Executive Officer, Director)
BoardJay Lichter, Ph.D.(Director)Brian Slingsby, M.D., Ph.D., M.P.H.(Director)Ed Hurwitz(Director)Ashish Xavier, Ph.D.(Director)Tighe Reardon(Executive Officer)
Developed selective small-molecule TRPML1 agonists for lysosomal storage diseases; acquired by Merck for up to $576M in 2019.
Developed selective small-molecule TRPML1 agonists for lysosomal storage diseases; acquired by Merck for up to $576M in 2019.
AeroRx is a clinical-stage biopharmaceutical company developing nebulized fixed-dose combination therapies (LABA/LAMA and triple LABA/LAMA/ICS) for moderate-to-severe COPD patients who are underserved by inhalers.
BiotechHealthtech
Ahmet Tutuncu(CEO and Co-founder)
Clinical-stage company developing tumor-activated immunotherapies using platform masking technology.
Developing therapeutic antibodies capable of entering cells and binding intracellular targets.
Phosphatase-focused immunotherapy drug discovery company; acquired by Boehringer-Ingelheim for up to $1.3B in 2024.
BiotechLa Jolla, US
Stefan Heller(Director)Sanford J. Madigan, Ph.D.(Executive Officer, Director)Jay Lichter, Ph.D.(Director)
BoardTighe Reardon(Executive Officer, Director)
Developed a first-in-class monoclonal antibody for multiple cancers; acquired by Cullinan Therapeutics in 2022.
Biotech addressing PROTAC delivery challenges using in situ carriers to deliver degraders to solid tumors.
Clinical-stage company developing broad-spectrum antibiotics from natural product scaffolds; partnered with Genentech.
Developed treatments for celiac disease; founded by Avalon Ventures and GSK, acquired by GSK in 2019.
BiotechLa Jolla, US
Miguel Garcia-Guzman(Executive Officer, Director)
BoardStefan Heller(Director)Sanford Madigan(Director)
Jnana Therapeutics operates a chemoproteomics-based drug discovery platform called RAPID to identify small molecule medicines targeting protein binding sites across multiple target classes.
BiotechDeep Tech
Rows marked βSEC filingβ are inferred from directors named on the company's SEC Form D β public regulatory data, not a portfolio list published by the firm.